Tissue and Blood‐Based Tumor Mutational Burden Predicts Treatment Response to PD ‐1 Blockade in Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta‐Analysis
Head & Neck · 2026
DOI: 10.1002/hed.70297 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Head & Neck, 2026. Verfasst von Xinmeng Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head and Neck, Zhujiang Hospital of Southern Medical University, Guangzhou, China. Hauptthemen laut MEDLINE: Squamous Cell Carcinoma of Head and Neck, Immune Checkpoint Inhibitors, Head and Neck Neoplasms, Mutation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 48 Literaturangaben.
Abstract (Originalsprache)
Background
Tumor mutational burden (TMB) is a predictive biomarker for immune checkpoint inhibitors (ICIs). Its clinical utility in head and neck squamous cell carcinoma (HNSCC) is limited by differences in detection approaches and inconsistent cut‐off values. In this meta‐analysis, we systematically reviewed multiple high‐quality studies to assess the predictive value of tissue‐based TMB (tTMB) and blood‐based TMB (bTMB) for treatment response of ICIs.
Methods
This study adhered to the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) guidelines. We systematically searched PubMed, Web of Science, Scopus, and SpringerLink for studies published through January 2026. Eligible studies included HNSCC patients treated with ICIs, with outcomes stratified by TMB status. The primary endpoint was objective response rate (ORR), and the secondary endpoints were overall survival (OS) and progression‐free survival (PFS). In addition, subgroup analyses were conducted to further explore between‐study differences according to different TMB detection approaches.
Results
We included 17 independent high‐quality cohorts comprising 1472 patients. High TMB was evaluated using two approaches: tTMB and bTMB, and this two‐modality framework was consistently applied to survival outcomes. Overall, high TMB showed prognostic utility across both tissue and blood measurements. Specifically, high TMB was associated with improved ORR (odds ratio [OR] = 2.80; 95% CI, 2.14–3.65; p < 0.001) with negligible heterogeneity ( I 2 = 0%). Similarly, superior outcomes were observed for OS (hazard ratio [HR] = 0.58; 95% CI, 0.51–0.67; p < 0.001) and PFS (HR = 0.66; 95% CI, 0.57–0.77; p < 0.001). Subgroup analysis of platform‐specific patterns revealed distinct cut‐off tendencies: tissue‐based targeted panels often clustered around a threshold of 10 mut/Mb, whereas blood‐based assays required higher cut‐offs (≥ 16 mut/Mb) to show predictive signals.
Conclusions
TMB shows promise as a predictive biomarker for objective response and survival in HNSCC patients receiving immunotherapy. In our analysis, both tTMB and bTMB were associated with improved objective response, although evidence for bTMB remains limited. Differences between tTMB and bTMB may contribute to variability in commonly used cut‐off values, which should be considered when interpreting results across studies and platforms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otolaryngology-Head and Neck, Zhujiang Hospital of Southern Medical University, Guangzhou, China.
- Guangdong Institute of Gastroenterology, Guangzhou, Guangdong, China.
- Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
- Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
ORCID-Profile: Xinmeng Wang, Huichuan Yu, Qian Cai
Zitieren
APA
Wang, X., Li, Z., Ouyang, F., Zheng, S., Yu, H., & Cai, Q. (2026). Tissue and Blood‐Based Tumor Mutational Burden Predicts Treatment Response to PD ‐1 Blockade in Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta‐Analysis. Head & Neck. https://doi.org/10.1002/hed.70297
Vancouver
Wang X, Li Z, Ouyang F, Zheng S, Yu H, Cai Q. Tissue and Blood‐Based Tumor Mutational Burden Predicts Treatment Response to PD ‐1 Blockade in Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta‐Analysis. Head & Neck. 2026. doi:10.1002/hed.70297
BibTeX
@article{Wang2026,
author = {Wang, Xinmeng and Li, Ziming and Ouyang, Feifan and Zheng, Shibei and Yu, Huichuan and Cai, Qian},
title = {Tissue and Blood‐Based Tumor Mutational Burden Predicts Treatment Response to PD ‐1 Blockade in Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta‐Analysis},
journal = {Head & Neck},
year = {2026},
doi = {10.1002/hed.70297}
}
EUVIMED